A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374 ↗

Phase 3 Recruiting 762 enrolled 89bio, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).

Timeline

Start: 2024-05-24
Primary completion: 2028-06
Completion: 2031-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pegozafermin	Protein / enzyme biologic	—	Subcutaneous

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Summary

Timeline

Drugs

Indications